Molecular Partners AG (OTCMKTS:MLLCF – Get Free Report)’s share price was down 25.8% during trading on Tuesday . The stock traded as low as $3.60 and last traded at $3.60. Approximately 500 shares changed hands during mid-day trading, a decline of 37% from the average daily volume of 789 shares. The stock had previously closed at $4.85.
Molecular Partners Price Performance
The business has a 50 day moving average price of $3.41 and a 200 day moving average price of $3.05.
Molecular Partners Company Profile
Molecular Partners AG is a clinical-stage biotechnology company headquartered in Zurich, Switzerland, specializing in the development of novel protein therapeutics based on its proprietary DARPin® (Designed Ankyrin Repeat Proteins) platform. The company’s pipeline focuses on precision molecules engineered for oncology and immuno-inflammatory diseases, as well as antiviral and anti-infective applications. By leveraging the modular nature of DARPin® science, Molecular Partners designs small, highly stable binding proteins that can engage multiple targets simultaneously, potentially improving efficacy and safety profiles over conventional antibody approaches.
Founded in 2004 by Professor Andreas Plückthun at the University of Zurich, Molecular Partners has advanced several clinical-stage candidates through Phase 1 and Phase 2 trials.
Read More
- Five stocks we like better than Molecular Partners
- MDA Space Targets US Defense Market With $620M Acquisition
- Carnival’s Second Quarter: Is the Stock Still Complicated?
- Domino’s Stock Slides to 52-Week Low as Investors Digest CEO Change
- Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
